HOME >> MEDICINE >> NEWS
ReQuip cuts risk of dyskinesias by 15-fold in early Parkinson's disease

Vancouver, Canada - A landmark, multinational, 5-year study shows that the dopamine-agonist ReQuip® (ropinirole hydrochloride, SmithKline Beecham) is associated with a much lower incidence of dyskinesias than L-dopa, and has comparable efficacy to L-dopa in the management of early Parkinson's Disease. The results of this exciting study are released today for the first time at the XIII International Congress on Parkinson's Disease (ICPD), Vancouver, 24-28 July, 1999.

"This landmark study should affect the future management of Parkinson's Disease. The data demonstrate that ropinirole is a first-line option for the initial treatment of early Parkinson's Disease," commented lead author of the study, Professor Olivier Rascol, Professor of Pharmacology at the Centre Hospitalier Universitaire, Toulouse, France.

"This is important news for patients, as we can now hope for good control of their symptoms with less risk of dyskinesias," concluded Dr Donald Calne, Chairman of the ICPD, and Director of the Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada.

The 268 patients participating in this double-blind controlled study, conducted in Europe, Israel and Canada, were randomised to receive either ReQuip® or L-dopa -- the current standard therapy. Both treatment groups were allowed to receive supplementary L-dopa if required.

The study demonstrated that the probability (odds ratio) of developing dyskinesias was 3.8 times higher for patients receiving L-dopa (incidence 46%) than for patients receiving ReQuip®, either alone or with additional L-dopa (incidence 20%). In patients who completed the trial on ReQuip® alone, the benefit was found to be even greater, with the relative probability of dyskinesias 15.2 times higher in the L-dopa group (incidence 36%) than the ReQuip® group (incidence 5%).

Over the 5-year study period, both groups of patients experienced similar control of their symptoms. A
'"/>

Contact: Kate Davies (Vancouver)
alexa@meditech.co.uk
44-780-840-345
MediTech Media Ltd.
26-Jul-1999


Page: 1 2

Related medicine news :

1. Clozapine effective for controlling dyskinesias in people with severe Parkinsons
2. New marker for early diagnosis of kidney failure identified
3. English-speaking Hispanic youth more likely to have sex early
4. Inpatient smoking cessation counseling is associated with early differences in mortality
5. Study finds no reason for expectant mothers to shy away from early epidurals
6. No increase in C-sections when epidural analgesia given early in labor
7. Radiologists offer non-surgical treatment for early-stage liver cancer
8. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
9. A new method for early detection of disease outbreaks
10. UCLA study: Nearly a third of drug ads in medical journals contain no references for medical claims
11. Morbidly obese pay nearly twice as much for health care

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ReQuip cuts risk dyskinesias fold early Parkinson disease

(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... In ... get help, leaving weeks or months later, relapsing and returning again, all at great ... the influence while in sober living homes or soon after leaving facilities who claim ...
(Date:8/27/2015)... ... ... According to an article published August 19 on Healio, The ... doctors and patients on the best practices for type 2 diabetes care. The article ... new version is taking into account nearly a decade of recent research data. While ...
(Date:8/27/2015)... ... August 27, 2015 , ... In mid-May, Logistics ... industry with the launch of its Doobster platform, a HIPAA-compliant mobile application that ... from their smart phones and tablets. Well, Doobster, “The App That Delivers!” ...
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... The ... will now be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. ... chin, Kybella provides permanent results without surgery. Dr. Kulak is the only Board ...
(Date:8/27/2015)... FL (PRWEB) , ... August 27, 2015 , ... ... announce its partnership with Julia Glushko, professional Tennis player for Israel in the ... uses Zensah® Compression for all her training and recovery. , With a focus ...
Breaking Medicine News(10 mins):Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3
(Date:8/27/2015)... Lilly and Company (NYSE: LLY ) will attend ... 17, 2015. Sue Mahony , Ph.D., senior vice ... Gaynor , M.D., senior vice president of product development ... a fireside chat at 3:30 p.m., Eastern Daylight Time. ... available on the "Webcasts & Presentations" section of Lilly,s ...
(Date:8/27/2015)... Ala. , Aug. 27, 2015 /PRNewswire/ ... Outpatient Pharmacy Provider (IOPP™) is expanding its ... of a medication-focused transition of care program ... named "RxCare Management," provides hospitals with technology ... hospital performance measures that have been mandated ...
(Date:8/27/2015)... 27, 2015   NineSigma the leading innovation partner ... in estimated overall revenue growth and anticipates the creation of ... Open Innovation Incentive (OII). In 2013, the ... grant of over $2 million to accelerate adoption of open ... Million and $1 Billion in revenues. To date over 45 ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3
Cached News: